Alpha Tau Medical Announces Third Quarter 2024 Financial Results and Provides Corporate Update
Provided By GlobeNewswire
Last update: Nov 19, 2024
- Alpha DaRT® accepted into the prestigious Total Product Life Cycle Advisory Program (TAP) of the FDA, to accelerate market access to the Alpha DaRT® for patients with recurrent glioblastoma multiforme (GBM) -
Read more at globenewswire.comNASDAQ:DRTSW (10/17/2025, 8:07:12 PM)
0.3225
+0.03 (+10.07%)
NASDAQ:DRTS (10/17/2025, 8:07:12 PM)
3.75
-0.14 (-3.6%)
Find more stocks in the Stock Screener
